Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics (Nasdaq: GANX) reported positive interim data from its Phase 1b study of GT-02287 in idiopathic and GBA1 Parkinson’s disease, presented at the 3rd International GBA1 Meeting 2026.
All 16 extension participants completed 150 days of dosing with stable MDS-UPDRS scores overall and a 4.8-point Part II+III difference favoring patients with high baseline CSF GluSph. According to Gain Therapeutics, CSF GluSph fell 81% after 90 days in patients with elevated baseline levels, with accompanying DDC decreases. Participants also commonly reported perceived improvements in smell and taste, balance or gait, and sleep. A Data Monitoring Committee recommended the study continue unchanged, and a Phase 2 trial is planned with objective smell and gait endpoints.
Gain Therapeutics (Nasdaq: GANX) reported Q1 2026 results and a corporate update centered on Parkinson’s candidate GT-02287 and GCase modulator GT-04686.
Q1 R&D was $2.8M, G&A $2.6M, net loss was $0.13 per share, and cash and securities totaled $16.5M.
Gain Therapeutics (NASDAQ: GANX) will deliver an oral presentation at the 3rd International GBA1 Meeting 2026 on May 22, 2026 in Phoenix, AZ. The talk is titled “An update on the development of the GCase modulator GT-02287 for Parkinson’s disease”.
Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, is listed as the presenter for a 15-minute session on May 22 at 4:15–4:30pm MST. Management will also attend the 7th World Parkinson’s Congress, May 24–27, 2026 in Phoenix.
Gain Therapeutics (Nasdaq: GANX) reported 2025 year-end results and a clinical update for lead candidate GT-02287. Key metrics: net loss $20.2M (2025), cash and marketable securities $20.8M at 12/31/25, R&D $10.2M, G&A $8.5M. Clinical highlights include Phase 1b extension enrollment of 16 participants (14 completed Day 150), an average 81% decrease in CSF GluSph after 90 days in participants with elevated baseline, and IND interaction with FDA with IND clearance expected in 2Q26. Phase 2 is expected to begin in 3Q26 and Phase 1b results are expected in 4Q26.
Gain Therapeutics (NASDAQ: GANX) announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026. The fireside chat is scheduled for March 23, 2026 at 11:30 a.m. PT.
Investors can access a live webcast or replay via the company website or contact ir@gaintherapeutics.com to arrange meetings through ROTH representatives.
Gain Therapeutics (NASDAQ: GANX) presented Phase 1b clinical and preclinical data at AD/PD 2026 supporting continued development of GT-02287 and a new chemical series led by GT-04686.
Key clinical signals include reductions in CSF glucosylsphingosine (GluSph) after 90 days, decreased CSF DOPA decarboxylase (DDC) in high‑GluSph participants, and durable MDS‑UPDRS scores through Day 150. The novel series is ready for IND‑enabling studies; the Part 1 safety profile supported a nine‑month extension expected to complete in September 2026.
Gain Therapeutics (NASDAQ: GANX) will present Phase 1b interim data for GT-02287 at AD/PD 2026 on March 18, 2026 and at a poster session March 17-21, 2026 in Copenhagen. The company reported CNS target engagement, pathway biomarker effects and early clinical improvement signals.
Gain submitted an IND response to the U.S. FDA in March 2026 and expects a reply in the coming weeks; the company remains on track to start a placebo-controlled Phase 2 trial in 3Q 2026.
Gain Therapeutics (Nasdaq: GANX) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, including a fireside chat at 1:20 p.m. ET.
A replay will be made available via the company website and investors can request one-on-one meetings through Oppenheimer or by contacting ir@gaintherapeutics.com.
Gain Therapeutics (NASDAQ: GANX) announced its participation in events during the week of the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 11–14, 2026.
Planned events include: the 9th Annual Sachs Neuroscience Innovation Forum on Jan 11, 2026 (presentation and one-on-ones; presentation at 2:40 p.m., Track C — Rosenberg Room, Marine's Memorial Club), the Demy-Colton/Informa Biotech Showcase on Jan 12–14, 2026 (presentation and one-on-ones; Hilton San Francisco Union Square), and the LifeSci Advisors 15th Annual Corporate Access Event on Jan 14, 2026 (one-on-one meetings; The Beacon Grand).
Investors can request in-person meetings via the Biotech Showcase partnering system or by registering/contacting LifeSci Advisors representative Alex Grossman (alex@lifesciadvisors.com).
Gain Therapeutics (Nasdaq: GANX) reported Phase 1b biomarker and clinical data for GT-02287 on January 6, 2026, showing biochemical and clinical signals after 90 days of dosing.
Key findings: in participants with elevated baseline cerebrospinal fluid glucosylsphingosine (GluSph), GluSph fell 81% on average after 90 days; as of Nov 30, 2025, 19 patients completed Part 1 (90 days), and 15 evaluable patients showed an average -2.20 point change in the sum of MDS‑UPDRS Part II+III (Part II: -0.6; Part III: -1.6). Four patients were excluded from MDS‑UPDRS analysis (two alpha-synuclein assay negative; two missing ‘off’ state scores). The company describes the GluSph reduction as a first-ever CSF observation after a GCase modulator and says results support continued development and evaluation in the dosing extension.